| 
			  
			
 
  by Krystle Barbour
 October 02, 
			2018
 from 
			MedicalSchool-UniversityOfMinnesota 
			Website
 
			
			Spanish 
			version
 
 
 
 
  
			Credit: 
			CC0 Public Domain 
			
 
 Previous research published earlier this year (Senolytics 
			improve Physical Function and increase Lifespan in Old Age) 
			in Nature Medicine involving,
 
				
					
					
					University of 
					Minnesota Medical School faculty Paul D. Robbins and Laura 
					J. Niedernhofer 
					
					Mayo Clinic 
					investigators James L. Kirkland and Tamara Tchkonia, 
					 
			...showed it was possible 
			to reduce the burden of damaged cells, termed senescent cells, 
			and extend lifespan and improve health, even when treatment was 
			initiated late in life.  
			  
			They now have shown that 
			treatment of aged mice with the natural product Fisetin,
			
			found in many fruits and vegetables, 
			also has significant positive effects on health and lifespan.
 As people age, they accumulate damaged cells. When the cells get to 
			a certain level of damage they go through an aging process of their 
			own, called
			
			cellular senescence.
 
			  
			The cells also release 
			inflammatory factors that tell the immune system to clear those 
			damaged cells. A younger person's immune system is healthy and is 
			able to clear the damaged cells. But as people age, they aren't 
			cleared as effectively.  
			  
			Thus they begin to 
			accumulate, cause low-level inflammation and release enzymes that 
			can degrade the tissue.
 Paul D. Robbins and fellow researchers found a natural 
			product, called
			
			Fisetin, reduces the level of these 
			damaged cells in the body. They found this by treating mice towards 
			the end of life with this compound and see improvement in health and 
			lifespan.
 
			  
			The paper, "Fisetin 
			is a Senotherapeutic that Extends Health and Lifespan," 
			was recently published in EBioMedicine. 
				
				"These results 
				suggest that we can extend the period of health, termed 
				healthspan, even towards the end of life," said Robbins. 
				   
				"But there are still 
				many questions to address, including the right dosage, for 
				example." 
			One question they can now 
			answer, however, is, 
				
				why haven't they done 
				this before?  
			There were always key 
			limitations when it came to figuring out how a drug will act on 
			different tissues, different cells in an aging body.  
			  
			Researchers didn't have a 
			way to identify if a treatment was actually attacking the particular 
			cells that are senescent, until now.
 Under the guidance of Edgar Arriaga, a professor in the 
			Department of Chemistry in the College of Science and Engineering 
			at the University of Minnesota, the team used mass cytometry, or
			
			CyTOF, technology and applied it 
			for the first time in aging research, which is unique to the 
			University of Minnesota.
 
				
				"In addition to 
				showing that the drug works, this is the first demonstration 
				that shows the effects of the drug on specific subsets of these 
				damaged cells within a given tissue," Robbins said.  
			  
			  |